Omega Therapeutics (OMGA)
US Market

Omega Therapeutics (OMGA) Income Statement


Omega Therapeutics Income Statement

Last quarter (Q2 2023), Omega Therapeutics's total revenue was $759.00K, an increase of 59.45% from the same quarter last year. In Q2, Omega Therapeutics's net income was $-29.69M. See Omega Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 2.60M$ 2.07M$ 144.00K$ 0.00$ 0.00
Cost of Revenue
$ 1.73M$ 3.02M$ 1.71M--
Gross Profit
$ 277.00K$ -949.00K$ -1.56M--
Operating Expense
$ 114.48M$ -104.84M$ -66.18M$ 28.64M$ 17.34M
Operating Income
$ -113.61M$ -102.77M$ -66.03M$ -28.64M$ -17.34M
Net Non Operating Interest Income Expense
$ 2.76M$ 1.30M$ 998.00K$ -777.00K$ -595.00K
Other Income Expense
$ 55.00K$ 157.00K$ 1.34M$ -25.00K$ -11.00K
Pretax Income
$ -111.59M$ -102.70M$ -68.28M$ -29.45M$ -17.95M
Tax Provision
$ -147.80M$ -147.80M$ -125.80M--
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -111.59M$ -102.70M$ -68.28M$ -29.45M$ -17.95M
Basic EPS
$ -2.64$ -2.14$ -3.05$ -1.14$ -0.69
Diluted EPS
$ -2.22$ -2.14$ -3.05$ -1.14$ -0.69
Basic Average Shares
$ 201.43M$ 47.88M$ 22.40M$ 25.91M$ 25.91M
Diluted Average Shares
$ 201.43M$ 47.88M$ 22.40M$ 25.91M$ 25.91M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 116.22M$ -101.82M$ -64.47M$ 28.64M$ 17.34M
Net Income From Continuing And Discontinued Operation
$ -111.59M$ -102.70M$ -68.28M$ -29.45M$ -17.95M
Normalized Income
$ -25.80M--$ -29.45M$ -17.95M
Interest Expense
---$ 777.00K$ 595.00K
$ -114.63M$ -104.22M$ -68.37M$ -28.67M$ -17.35M
$ -78.45M$ -97.88M$ -66.85M$ -27.52M$ -16.56M
Currency in USD

Omega Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis